Results for tag: "Degarelix"

Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist used to treat prostate cancer. It works by blocking the release of hormones that stimulate the growth of prostate cancer cells. It is administered as an intramuscular injection and is typically used in combination with other treatments such as radiation therapy and chemotherapy. Degarelix is approved by the US Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. The Degarelix market is highly competitive, with several major players offering similar products. The market is expected to grow in the coming years due to the increasing prevalence of prostate cancer and the growing demand for effective treatments. Additionally, the development of new formulations and delivery systems is expected to further drive the market growth. Some of the major companies in the Degarelix market include Ferring Pharmaceuticals, Astellas Pharma, Sanofi, Pfizer, and Bayer. Show Less Read more